Exelixis

Youtube Subscribe

Open: 21.5 Close: 21.51 Change: 0.01

Stop waiting time to find out about Exelixis: Our AI summarizes all info about it.

How much time have you spent trying to decide whether investing in Exelixis? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Exelixis are: Exelixis, cancer, …

Concept Map

Semantic Network

Stock Summary

Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell.

Today's Summary

Exelixis stock has gained 34% since 2022 primarily due to favorable change in price to sales multiple (p/s) ExelIXis investors are up 6.2% in the past week, but earnings have declined. The lack of early success in its lead drugs cancer trial scares the market, but we see a buying opportunity.

Today's News

Exelixis stock has gained 34% since 2022 primarily due to favorable change in price to sales multiple (p/s) Why ExelIXis Stock Moved: EXEL Stock Has Gained 34% Since 2022. Exelixis stock price today (nasdaq: exel) quote, market cap, chart, chart | wallstreetzen.com. ExelIXis investors are up 6.2% in the past week, but earnings have declined. Exelixis Incorporated (NASDAQ: EXEL) is a biotech company known for CABOMETYX - a medicine for renal cell carcinoma (the most common type of kidney cancer) and common liver cancers. The firm is expanding its treatments into colorectal and prostate cancer. Exelixis, Inc. - consensus buy rating and 23.8% upside potential. - Consensus ‘buy’ rating and ‘23.8’ Upside Potential Charlotte Edwards August 9, 2023 12:50 pm Sharing Link : https://1lo.co/w7JK9 Share Price as of August 14 4:00 PM EST. Exelixis Inc shares are currently trading up about 2.7% on the day. S&P Equity Research maintained a hold rating and $9 price target on ExelIXis. The main point of investing for the long term is to make money. Investors will continue to monitor Exelixis closely as they evaluate the companys ability to adapt and deliver on projected earnings. Point72 Asset Management L.P. has raised its stake in ExelIXis by a staggering 595.4% during the fourth quarter. Assenagon Asset Management S.A. increased its stake by an impressive 67.9% during first quarter. Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. The lack of early success in its lead drugs cancer trial scares the market, but we see a buying opportunity. The company offers comprehensive employee benefits package.

Stock Profile

"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California."

Keywords

The game is changing. There is a new strategy to evaluate Exelixis fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Exelixis are: Exelixis, cancer, ExelIXis, price, buy, rating, stock, and the most common words in the summary are: exelixis, stock, inc, job, market, exel, price, . One of the sentences in the summary was: The lack of early success in its lead drugs cancer trial scares the market, but we see a buying opportunity.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #exelixis #stock #inc #job #market #exel #price.

Read more →

Youtube Subscribe

---